The BareStory
President Donald Trump on Thursday, January 15, announced a new proposal titled "The Great Healthcare Plan," urging Congress to enact the framework immediately. The White House stated the initiative is designed to lower health insurance premiums and prescription drug costs, primarily by directing federal funds to individuals to purchase their own care rather than providing subsidies to insurance companies.
According to the administration, the plan would require hospitals and providers accepting Medicare or Medicaid to publicly post their prices. The framework also proposes codifying a "most-favored-nation" policy to align U.S. drug prices with lower foreign rates and utilizes agreements with pharmaceutical companies to offer discounted medicines. The President claimed the proposal would reduce costs by eliminating "government payoffs" to insurers.
The announcement comes as lawmakers struggle to negotiate an extension of enhanced Affordable Care Act (ACA) subsidies, which expired at the beginning of the year. While the House recently passed a three-year extension, the measure has stalled in the Senate. According to federal data, the expiration of these benefits coincided with approximately 14 million fewer people enrolling in ACA plans compared to the previous year.
The President’s proposal does not include the subsidy extension currently under debate. A White House official stated the administration prefers sending funds directly to consumers but noted the plan does not explicitly rule out extending the ACA credits. Senators involved in the negotiations expressed mixed reactions, with some questioning whether the new framework would hinder efforts to restore the lapsed subsidies.
How it may affect me
As a U.S. reader:
• You may face higher insurance premiums or gaps in coverage following the recent expiration of enhanced ACA subsidies, which coincided with 14 million fewer people enrolling in plans.
• Under the new proposal, you might receive federal funds directly to purchase healthcare, representing a shift from the current model of government subsidies paid to insurance companies.
• You could encounter new price transparency measures at hospitals accepting Medicare or Medicaid and potential drug cost changes through proposed policies aligning U.S. prices with foreign rates.
• You may experience ongoing uncertainty regarding healthcare financial support as the Senate weighs restoring lapsed subsidies against the President's new framework emphasizing direct consumer funding.
